Predict your next investment

Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Scientific, Engineering Software
sciex.com

See what CB Insights has to offer

Partners & Customers

10

About SCIEX

SCIEX specializes in life science analytical technologies.

SCIEX Headquarter Location

71 Four Valley Drive

Concord, Ontario, L4K 4V8,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SCIEX

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find SCIEX in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,312 items

Companies that received FDA De Novo clearances since 2010. Companies tagged as #FDADeNovos

SCIEX Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SCIEX Rank

Latest SCIEX News

Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies

Jan 10, 2022

Redwood City, California, UNITED STATES REDWOOD CITY, Calif. and HUNTSVILLE, Ala. and FRAMINGHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics; SCIEX, a global leader in life science analytical technologies; and Discovery Life Sciences (Discovery), a global leader in biomarker development and biospecimen solutions utilizing proteomic, genomic, cell, and immunohistochemistry (IHC) technologies, today announced they have signed an agreement to form the Proteogenomics Consortium, a collaboration that will enable genomics customers to more easily add deep, unbiased proteomics data to their discovery, translational and clinical studies. Through this multi-year effort, Discovery will establish, expand, and offer deep, unbiased proteomics capabilities to their existing genomics customers using the Seer Proteograph Product Suite and the SCIEX ZenoTOF 7600 platform. This will create a capacity for more than one billion peptides each year to be analyzed and cataloged, allowing the discovery of new protein variants and novel biomarkers, potentially leading to therapeutic breakthroughs. Seer and SCIEX will contribute industry-leading proprietary proteomics technologies and instrumentation, and Discovery will provide its significant scale and expertise in genomics services and biospecimens, to provide services that support population-scale plasma proteogenomic projects. Seer’s Proteograph Product Suite includes proprietary engineered nanoparticles, consumables, an automation instrument, and software that enables deep, unbiased proteomics studies with an unprecedented combination of speed, scale, depth, and breadth of data. It accurately surveys thousands of proteins and millions of peptides with precision. The SCIEX ZenoTOF 7600 system is a high-resolution, accurate mass system combining the power of Zeno trap pulsing with electron activated dissolution (EAD) fragmentation technology to uncover structural information, previously inaccessible, and drive the limits of quantification achievable with accurate mass. Discovery will expand their existing biomarker discovery platform as part of their proteomics strategy, expanding the technology platforms available to their worldwide customer base. Their unique service-oriented scientific team will deliver reliable scientific insight for proteogenomic studies. A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/768575cc-383e-468e-a396-e5d71e472bfb “This is a highly innovative and novel partnership wherein, for the first time, three scientific service and technology industry leaders are dedicating and combining resources at this scale to advance proteogenomic research. This collaboration will overcome existing research challenges and accelerate progress in our understanding of human health and disease by helping our customers significantly expand and accelerate their multi-omics efforts,” said Glenn Bilawsky, CEO of Discovery Life Sciences. “Rapid acquisition of data speeds development. This Consortium will provide new, highly-scaled and more comprehensive capabilities to develop and deploy novel biomarkers, drug candidates, and diagnostics.” “We are entering a new era where progress is expected at pandemic speed. This collaboration and its commitment to proteogenomic accessibility will help accelerate many new discoveries for disease research. Sensitive detection and robust quantitation of biomarkers are foundational to Precision Medicine, and support earlier and better diagnosis, along with more personalized and effective treatments,” said Joe Fox, President at SCIEX. “We are thrilled to collaborate with Discovery Life Sciences and SCIEX to bring unbiased, deep proteogenomics at scale to the market,” said Omid Farokhzad, CEO and Founder at Seer. “Through our collaboration, we will empower genomics researchers to add unbiased, deep proteomics data to their studies, connecting genotype to phenotype, and enabling multi-omic studies of unprecedented resolution.” The Proteogenomics Consortium aims to significantly expand our understanding of the proteome in an unbiased manner across a variety of cohorts and disease states. With a phased approach to building a 100,000 sample per-year capacity, the Proteogenomics Consortium plans to create the workflows and expertise to run large-scale proteogenomic projects efficiently, quickly, and robustly. Through the Consortium there is also an opportunity for future collaborations to further pave the way for adoption of proteogenomics via workflow optimization and joint publications. About Discovery Life Sciences Discovery Life Sciences is the global market leader in Biospecimen analysis, procurement, distribution, and Biomarker Services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s globally recognized sequencing and bioinformatics division that leverages the most current short- and long-read genomic analysis technologies to support discovery, translational, and clinical research comprehensively. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to support the rapid acquisition and analysis of data to support decision making and the deployment of new innovations. We are Science at your Service™. For more information, visit dls.com . About SCIEX SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes. Today, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives. For more information, please visit  sciex.com About Seer Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit  www.seer.bio . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s ability to successfully execute the development and commercialization of its Proteograph or the combined solution offered by the Consortium agreement, the capacity to analyze and catalog more than one billion peptides each year, the discovery of new protein variants, novel biomarkers leading to therapeutic breakthroughs, the ability of the combined product offering to enable labs to perform unbiased, deep proteomics studies at scale to deliver new levels of insight, speed, and sensitivity, to expand unbiased proteomics discovery efforts, expand application sets, and future collaborations. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Seer Media Contact:

SCIEX Acquisitions

2 Acquisitions

SCIEX acquired 2 companies. Their latest acquisition was Intabio on January 21, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/21/2021

Series B

$99M

$29.5M

Acquired

6

11/15/2011

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/21/2021

11/15/2011

Investment Stage

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$29.5M

Note

Acquired

Subscribe to see more

Sources

6

0

SCIEX Partners & Customers

10 Partners and customers

SCIEX has 10 strategic partners and customers. SCIEX recently partnered with Evosep on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/1/2021

Partner

Evosep

Denmark

SCIEX and Evosep Will Collaborate to Provide Robust, High-Throughput Proteomics Workflows

Today , SCIEX and Evosep announce an agreement to co-market products together to improve robust , high-throughput proteomics workflows for precision medicine .

3

7/29/2021

Partner

Genedata

Switzerland

Strategic Partnership Between Genedata and SCIEX Deepens and Accelerates Characterization of Next Generation Biotherapeutics

The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .

1

7/29/2021

Partner

Genedata

Switzerland

Strategic partnership between Genedata and SCIEX deepens and accelerates characterization of next generation biotherapeutics

The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .

1

5/11/2021

Client

Waters

United States

Subscribe to see more

Subscribe to see more

10

3/29/2021

Licensee

Seer

United States

Subscribe to see more

Subscribe to see more

10

Date

11/1/2021

7/29/2021

7/29/2021

5/11/2021

3/29/2021

Type

Partner

Partner

Partner

Client

Licensee

Business Partner

Evosep

Genedata

Genedata

Waters

Seer

Country

Denmark

Switzerland

Switzerland

United States

United States

News Snippet

SCIEX and Evosep Will Collaborate to Provide Robust, High-Throughput Proteomics Workflows

Today , SCIEX and Evosep announce an agreement to co-market products together to improve robust , high-throughput proteomics workflows for precision medicine .

Strategic Partnership Between Genedata and SCIEX Deepens and Accelerates Characterization of Next Generation Biotherapeutics

The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .

Strategic partnership between Genedata and SCIEX deepens and accelerates characterization of next generation biotherapeutics

The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

SCIEX Team

5 Team Members

SCIEX has 5 team members, including current President, Inese Lowenstein.

Name

Work History

Title

Status

Inese Lowenstein

President

Current

Dominic Gostick

Chief Technology Officer

Current

Gordon Logan

Senior Vice President

Current

Subhakar Dey

Owner

Current

Andrew Clark

Chief Financial Officer

Former

Name

Inese Lowenstein

Dominic Gostick

Gordon Logan

Subhakar Dey

Andrew Clark

Work History

Title

President

Chief Technology Officer

Senior Vice President

Owner

Chief Financial Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.